{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T23:01:21Z","timestamp":1769382081392,"version":"3.49.0"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.pharep.2016.03.016","type":"journal-article","created":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T16:48:13Z","timestamp":1460566093000},"page":"737-747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Current and future trends in the lipid lowering therapy"],"prefix":"10.1007","volume":"68","author":[{"given":"Bogus\u0142aw","family":"Okopie\u0144","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Bu\u0142dak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Bo\u0142dys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2016.03.016_bib0810","unstructured":"Cardiovascular diseases statistics. Data extracted in October 2015. Available from: http:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php\/Cardiovascular_diseases_statistics#Deaths_from_cardiovascular_diseases"},{"issue":"1","key":"10.1016\/j.pharep.2016.03.016_bib0815","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","article-title":"Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges","volume":"14","author":"Sampson","year":"2012","journal-title":"Curr Atheroscler Rep"},{"issue":"9","key":"10.1016\/j.pharep.2016.03.016_bib0820","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.numecd.2013.05.002","article-title":"Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update","volume":"23","author":"Reiner","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"11","key":"10.1016\/j.pharep.2016.03.016_bib0825","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.mayocp.2013.09.003","article-title":"Lipoprotein(a), cardiovascular disease, and contemporary management","volume":"88","author":"Jacobson","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"14","key":"10.1016\/j.pharep.2016.03.016_bib0830","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharep.2016.03.016_bib0835","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MOL.0b013e3283319a1d","article-title":"Severe hypertriglyceridemia and pancreatitis: presentation and management","volume":"20","author":"Ewald","year":"2009","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"10.1016\/j.pharep.2016.03.016_bib0840","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2015.01.039","article-title":"New insights into the pathophysiology of dyslipidemia in type 2 diabetes","volume":"239","author":"Taskinen","year":"2015","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.pharep.2016.03.016_bib0845","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2011.06.011","article-title":"The new joint EAS\/ESC guidelines for the management of dyslipidaemias","volume":"217","author":"Catapano","year":"2011","journal-title":"Atherosclerosis"},{"issue":"25 Pt B","key":"10.1016\/j.pharep.2016.03.016_bib0850","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.pharep.2016.03.016_bib0855","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pharep.2016.03.016_bib0860","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.pharep.2016.03.016_bib0865","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib0870","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jacl.2014.02.012","article-title":"An assessment by the Statin Diabetes Safety Task Force: 2014 update","volume":"8","author":"Maki","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"9","key":"10.1016\/j.pharep.2016.03.016_bib0875","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.bbadis.2015.05.015","article-title":"Recent insights on the role of cholesterol in non-alcoholic fatty liver disease","volume":"1852","author":"Arguello","year":"2015","journal-title":"Biochim Biophys Acta BBA \u2013 Mol Basis Dis"},{"issue":"10","key":"10.1016\/j.pharep.2016.03.016_bib0880","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.metabol.2015.07.003","article-title":"Nonalcoholic fatty liver disease and statins","volume":"64","author":"Tziomalos","year":"2015","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib0885","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2014.03.003","article-title":"NLA Task Force on Statin Safety \u2013 2014 update","volume":"8","author":"Jacobson","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib0890","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jacl.2014.02.013","article-title":"An assessment by the Statin Cognitive Safety Task Force: 2014 update","volume":"8","author":"Rojas-Fernandez","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib0895","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","article-title":"An assessment by the Statin Liver Safety Task Force: 2014 update","volume":"8","author":"Bays","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib0900","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib0905","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"A clinician's guide to statin drug\u2013drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib0910","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","article-title":"An assessment by the Statin Intolerance Panel: 2014 update","volume":"8","author":"Guyton","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.pharep.2016.03.016_bib0915","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cmet.2008.05.001","article-title":"Ezetimibe blocks internalization of the NPC1L1\/cholesterol complex","volume":"7","author":"Chang","year":"2008","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib0920","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.14.99","article-title":"Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia","volume":"14","author":"Davis","year":"2007","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.pharep.2016.03.016_bib0925","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1567-5688(15)50007-X","article-title":"The effect of ezetimibe on NAFLD","volume":"17","author":"Averna","year":"2015","journal-title":"Atheroscler Suppl"},{"issue":"6","key":"10.1016\/j.pharep.2016.03.016_bib0930","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/ajcn\/81.6.1351","article-title":"Plant sterols are efficacious in lowering plasma LDL and non-HDL cholesterol in hypercholesterolemic type 2 diabetic and nondiabetic persons","volume":"81","author":"Lau","year":"2005","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.pharep.2016.03.016_bib0935","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jff.2012.08.001","article-title":"Impact of omega-3 fatty acids and\/or plant sterol supplementation on non-HDL cholesterol levels of dyslipidemic Indian adults","volume":"5","author":"Khandelwal","year":"2013","journal-title":"J Funct Foods"},{"issue":"1","key":"10.1016\/j.pharep.2016.03.016_bib0940","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2008.06.026","article-title":"New insights into the molecular actions of plant sterols and stanols in cholesterol metabolism","volume":"203","author":"Calpe-Berdiel","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharep.2016.03.016_bib0945","first-page":"CD001918","article-title":"Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia","volume":"6","author":"Malhotra","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.pharep.2016.03.016_bib0950","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.atherosclerosis.2013.11.043","article-title":"Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease","volume":"232","author":"Gylling","year":"2014","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.pharep.2016.03.016_bib0955","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11883-015-0495-8","article-title":"Red yeast rice for the treatment of dyslipidemia","volume":"17","author":"Burke","year":"2015","journal-title":"Curr Atheroscler Rep"},{"issue":"7\u20138","key":"10.1016\/j.pharep.2016.03.016_bib0960","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1345\/aph.10263","article-title":"Colesevelam hydrochloride: a novel bile acid-binding resin","volume":"35","author":"Aldridge","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"16","key":"10.1016\/j.pharep.2016.03.016_bib0965","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1001\/archinte.159.16.1893","article-title":"Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects","volume":"159","author":"Davidson","year":"1999","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.pharep.2016.03.016_bib0970","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40256-013-0037-0","article-title":"Role of colesevelam in combination lipid-lowering therapy","volume":"13","author":"Jones","year":"2013","journal-title":"Am J Cardiovasc Drugs Drugs Dev Interv"},{"key":"10.1016\/j.pharep.2016.03.016_bib0975","article-title":"Colesevelam as an add-on treatment for control of dyslipidemia and hyperglycemia in type 2 diabetes","author":"Sandhu","year":"2015","journal-title":"Can J Diabetes"},{"issue":"2","key":"10.1016\/j.pharep.2016.03.016_bib0980","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharep.2016.03.016_bib0985","unstructured":"Serometrix Homepage. Available from: http:\/\/www.serometrix.com\/pipeline.html [Accessed December 2015]."},{"key":"10.1016\/j.pharep.2016.03.016_bib0990","unstructured":"SPC-5001. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01350960?term=SPC-5001&rank=1 [Accessed December 2015]."},{"key":"10.1016\/j.pharep.2016.03.016_bib0995","unstructured":"ALN-PCS02. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01437059?term=ALN-PCS02&rank=1 [Accessed December 2015]."},{"issue":"16","key":"10.1016\/j.pharep.2016.03.016_bib1000","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.pharep.2016.03.016_bib1005","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMe1502192","article-title":"Lowering LDL cholesterol is good, but how and in whom?","volume":"372","author":"Stone","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharep.2016.03.016_bib1010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib1015","doi-asserted-by":"crossref","first-page":"e60095","DOI":"10.1371\/journal.pone.0060095","article-title":"Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels","volume":"8","author":"Berthold","year":"2013","journal-title":"PLOS ONE"},{"issue":"5","key":"10.1016\/j.pharep.2016.03.016_bib1020","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.pharep.2016.03.016_bib1025","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11883-013-0382-0","article-title":"Novel therapies for treating familial hypercholesterolemia","volume":"16","author":"Bandeali","year":"2014","journal-title":"Curr Atheroscler Rep"},{"issue":"16","key":"10.1016\/j.pharep.2016.03.016_bib1030","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"issue":"9860","key":"10.1016\/j.pharep.2016.03.016_bib1035","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.pharep.2016.03.016_bib1040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.atherosclerosissup.2015.02.017","article-title":"Treatment of primary hypertriglyceridemia states \u2013 general approach and the role of extracorporeal methods","volume":"18","author":"Stefanutti","year":"2015","journal-title":"Atheroscler Suppl"},{"issue":"4","key":"10.1016\/j.pharep.2016.03.016_bib1045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jacl.2015.05.001","article-title":"Treating homozygous familial hypercholesterolemia in a real-world setting: experiences with lomitapide","volume":"9","author":"Roeters van Lennep","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pharep.2016.03.016_bib1050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2261-5-30","article-title":"JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs","volume":"5","author":"Aggarwal","year":"2005","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib1055","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1124\/jpet.110.177527","article-title":"A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile","volume":"337","author":"Kim","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2016.03.016_bib1060","unstructured":"SLx-4090 in chylomicronemia. 2015 Oct. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01675154"},{"issue":"9","key":"10.1016\/j.pharep.2016.03.016_bib1065","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Visser","year":"2012","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.pharep.2016.03.016_bib1070","doi-asserted-by":"crossref","first-page":"e49006","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pharep.2016.03.016_bib1075","unstructured":"Refusal of the marketing authorisation for Kynamro (mipomersen). Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002429\/WC500140678.pdf [Accessed December 2015]."},{"issue":"2","key":"10.1016\/j.pharep.2016.03.016_bib1080","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacl.2014.12.006","article-title":"Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials","volume":"9","author":"Panta","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pharep.2016.03.016_bib1085","unstructured":"a study of the safety and efficacy of two different regimens of mipomersen in patients with familial hypercholesterolemia and inadequately controlled low-density lipoprotein cholesterol (FOCUS FH). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01475825?term=focus+fh&rank=1 [Accessed December 2015]."},{"issue":"5","key":"10.1016\/j.pharep.2016.03.016_bib1090","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2147\/VHRM.S3390","article-title":"Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing","volume":"4","author":"Farnier","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.pharep.2016.03.016_bib1095","doi-asserted-by":"crossref","first-page":"271983","DOI":"10.1155\/2015\/271983","article-title":"Peroxisome proliferator-activated receptors and the heart: lessons from the past and future directions","volume":"2015","author":"Lee","year":"2015","journal-title":"PPAR Res"},{"issue":"17","key":"10.1016\/j.pharep.2016.03.016_bib1100","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"ACCORD. Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharep.2016.03.016_bib1105","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1475-2840-12-82","article-title":"Selective peroxisome proliferator-activated receptor \u03b1 modulators (SPPARM\u03b1): the next generation of peroxisome proliferator-activated receptor \u03b1-agonists","volume":"12","author":"Fruchart","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pharep.2016.03.016_bib1110","first-page":"CD009580","article-title":"Fibrates for secondary prevention of cardiovascular disease and stroke","volume":"10","author":"Wang","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"6A","key":"10.1016\/j.pharep.2016.03.016_bib1115","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.pharep.2016.03.016_bib1120","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jacl.2012.01.002","article-title":"A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova\u00ae compared to Lovaza\u00ae in a pharmacokinetic single-dose evaluation) study","volume":"6","author":"Davidson","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pharep.2016.03.016_bib1125","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1475-2840-12-100","article-title":"Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200\u2013500mg\/dL), and on statin therapy at LDL-C goal: the ANCHOR study","volume":"12","author":"Brinton","year":"2013","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.pharep.2016.03.016_bib1130","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacl.2012.07.001","article-title":"Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)","volume":"6","author":"Bays","year":"2012","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.pharep.2016.03.016_bib1135","first-page":"681","article-title":"Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency","volume":"11","author":"Burnett","year":"2009","journal-title":"Curr Opin Mol Ther"},{"issue":"2","key":"10.1016\/j.pharep.2016.03.016_bib1140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40265-014-0339-9","article-title":"Alipogene Tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.pharep.2016.03.016_bib1145","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrd4279","article-title":"HDL-targeted therapies: progress, failures and future","volume":"13","author":"Kingwell","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"2\u20133","key":"10.1016\/j.pharep.2016.03.016_bib1150","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0021-9150(91)90114-I","article-title":"Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency","volume":"90","author":"Koizumi","year":"1991","journal-title":"Atherosclerosis"},{"issue":"21","key":"10.1016\/j.pharep.2016.03.016_bib1155","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"issue":"9983","key":"10.1016\/j.pharep.2016.03.016_bib1160","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(14)62115-2","article-title":"Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"385","author":"Kastelein","year":"2015","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.pharep.2016.03.016_bib1165","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharep.2016.03.016_bib1170","unstructured":"Accelerate terminated. Available from: https:\/\/investor.lilly.com\/releasedetail.cfm?ReleaseID=936130 [Accessed 12.12.15]."},{"issue":"1","key":"10.1016\/j.pharep.2016.03.016_bib1175","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jacl.2014.10.005","article-title":"Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial","volume":"9","author":"Brinton","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.pharep.2016.03.016_bib1180","doi-asserted-by":"crossref","first-page":"e111529","DOI":"10.1371\/journal.pone.0111529","article-title":"A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit","volume":"9","author":"Liaw","year":"2014","journal-title":"PLOS ONE"},{"issue":"6","key":"10.1016\/j.pharep.2016.03.016_bib1185","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2217\/clp.13.73","article-title":"Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics","volume":"8","author":"Larach","year":"2013","journal-title":"Clin Lipidol"},{"issue":"23","key":"10.1016\/j.pharep.2016.03.016_bib1190","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pharep.2016.03.016_bib1195","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharep.2016.03.016_bib1200","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.atherosclerosis.2015.04.115","article-title":"ISIS-ANGPTL3RX, an antisense inhibitor to angiopoietin-like 3, reduces plasma lipid levels in mouse models and in healthy human volunteers","volume":"241","author":"Brandt","year":"2015","journal-title":"Atherosclerosis"},{"issue":"15","key":"10.1016\/j.pharep.2016.03.016_bib1205","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2010.10.052","article-title":"Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice","volume":"57","author":"Merki","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pharep.2016.03.016_bib1210","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.pharep.2016.03.016_bib1215","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.atherosclerosis.2014.10.099","article-title":"ETC-1002: a future option for lipid disorders?","volume":"237","author":"Nikolic","year":"2014","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib1220","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pharep.2016.03.016_bib1225","unstructured":"Planned Studies of ETC-1002. Available from: http:\/\/www.esperion.com\/therapies-progress\/clinical-studies\/ [Accessed December 2015]."},{"key":"10.1016\/j.pharep.2016.03.016_bib1230","unstructured":"etc-1002 in clinicaltrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/results?term=etc-1002&Search=Search [Accessed December 2015]."},{"issue":"2","key":"10.1016\/j.pharep.2016.03.016_bib1235","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1124\/jpet.109.154047","article-title":"Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster","volume":"330","author":"King","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.pharep.2016.03.016_bib1240","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12944-015-0006-5","article-title":"Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome","volume":"14","author":"Meyers","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.pharep.2016.03.016_bib1245","unstructured":"Efficacy of LCQ908 on Cardiovascular Risk (im). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01474434?term=lcq908&rank=4 [Accessed December 2015]."},{"key":"10.1016\/j.pharep.2016.03.016_bib1250","unstructured":"A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00901979?term=lcq908&rank=10 [Accessed December 2015]."},{"issue":"9","key":"10.1016\/j.pharep.2016.03.016_bib1255","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/jcph.509","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects","volume":"55","author":"Meyers","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib1260","first-page":"179","article-title":"Therapeutic approaches to drug targets in atherosclerosis","volume":"22","author":"Jamkhande","year":"2014","journal-title":"Saudi Pharm J SPJ Off Publ Saudi Pharm Soc"},{"issue":"24","key":"10.1016\/j.pharep.2016.03.016_bib1265","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1161\/01.CIR.97.24.2433","article-title":"Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization","volume":"97","author":"Aikawa","year":"1998","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharep.2016.03.016_bib1270","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1527-3466.2007.00030.x","article-title":"Inhibition of Acyl-CoA cholesterol acyltransferase by F12511 (Eflucimibe): Could it be a new antiatherosclerotic therapeutic? Eflucimibe (F12511)","volume":"26","author":"L\u00f3pez-Farr\u00e9","year":"2008","journal-title":"Cardiovasc Drug Rev"},{"issue":"12","key":"10.1016\/j.pharep.2016.03.016_bib1275","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMoa054699","article-title":"Effect of ACAT inhibition on the progression of coronary atherosclerosis","volume":"354","author":"Nissen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharep.2016.03.016_bib1280","unstructured":"A trial of the safety efficacy of K-604 for the treatment of atherosclerosis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00851500?term=k604&rank=1 [Accessed December 2015]."},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib1285","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/j.1552-4604.1993.tb03948.x","article-title":"Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study","volume":"33","author":"Ghirlanda","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharep.2016.03.016_bib1290","unstructured":"Discontinuation of development of TAK-475, a compound for treatment of hypercholesterolemia. Available from: http:\/\/www.takeda.com\/news\/2008\/20080328_3603html [Accessed December 2015]."},{"issue":"4","key":"10.1016\/j.pharep.2016.03.016_bib1295","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/dom.12221","article-title":"Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial","volume":"16","author":"Denison","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.pharep.2016.03.016_bib1300","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1021\/ml400151c","article-title":"Discovery of DF-461, a potent squalene synthase inhibitor","volume":"4","author":"Ichikawa","year":"2013","journal-title":"ACS Med Chem Lett"},{"issue":"23","key":"10.1016\/j.pharep.2016.03.016_bib1305","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1111\/bph.13029","article-title":"The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges","volume":"172","author":"Cheang","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"15","key":"10.1016\/j.pharep.2016.03.016_bib1310","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2014.3321","article-title":"Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial","volume":"311","author":"Lincoff","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.pharep.2016.03.016_bib1315","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.plipres.2014.07.002","article-title":"Recent advances in pharmacotherapy for hypertriglyceridemia","volume":"56","author":"Sahebkar","year":"2014","journal-title":"Prog Lipid Res"},{"issue":"9","key":"10.1016\/j.pharep.2016.03.016_bib1320","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1161\/ATVBAHA.112.247890","article-title":"Lipid effects of peroxisome proliferator-activated receptor-\u03b4 agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome","volume":"32","author":"Olson","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.pharep.2016.03.016_bib1325","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.atherosclerosis.2011.10.029","article-title":"Effects of the PPAR-\u03b4 agonist MBX-8025 on atherogenic dyslipidemia","volume":"220","author":"Choi","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharep.2016.03.016_bib1330","unstructured":"Study to evaluate the effects of MBX-8025 in patients with HoFH. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02472535?term=mbx8025&rank=2 [Accessed December 2015]."},{"issue":"9","key":"10.1016\/j.pharep.2016.03.016_bib1335","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/dc11-0093","article-title":"Effects of the new dual PPAR \u03b1\/\u03b4 agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism","volume":"34","author":"Cariou","year":"2011","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.pharep.2016.03.016_bib1340","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.2337\/dc12-2012","article-title":"Dual peroxisome proliferator-activated receptor \u03b1\/\u03b4 agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects","volume":"36","author":"Cariou","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharep.2016.03.016_bib1345","unstructured":"Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01694849?term=gft505&rank=4 [Accessed December 2015]."},{"key":"10.1016\/j.pharep.2016.03.016_bib1350","unstructured":"Elafibranor Phase III. Available from: http:\/\/www.genfit.com\/wp-content\/uploads\/2015\/11\/2015.11.16-PR-GENFIT-Ph3-Elafibranor.pdf [Accessed 12.12.15]."},{"key":"10.1016\/j.pharep.2016.03.016_bib1355","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.pharep.2016.03.016_bib1360","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1517\/13543784.2015.1006359","article-title":"Early investigational drugs targeting PPAR-\u03b1 for the treatment of metabolic disease","volume":"24","author":"Liu","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pharep.2016.03.016_bib1365","unstructured":"K-877 Japanese Clinical Trials. Available from: http:\/\/www.clinicaltrials.jp\/user\/search\/directCteDetail.jsp?clinicalTrialId=13036 [Accessed October 2015]."},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib1370","doi-asserted-by":"crossref","first-page":"E513","DOI":"10.1208\/aapsj070352","article-title":"Model-based development of gemcabene, a new lipid-altering agent","volume":"7","author":"Mandema","year":"2005","journal-title":"AAPS J"},{"issue":"5","key":"10.1016\/j.pharep.2016.03.016_bib1375","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9149(03)00721-5","article-title":"Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol","volume":"92","author":"Bays","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharep.2016.03.016_bib1380","unstructured":"Gemcabene web page. Available from: http:\/\/www.gemphire.com\/products.php [Accessed September 2015]."},{"key":"10.1016\/j.pharep.2016.03.016_bib1385","unstructured":"Phase 1 single and multiple ascending dose study of CAT-2003, a novel activator of lipoprotein lipase, demonstrates reductions in postprandial triglycerides. Available from: http:\/\/www.businesswire.com\/news\/home\/20140331005014\/en\/Catabasis-Present-CAT-2003-Data-American-College-Cardiology%E2%80%99s."},{"issue":"11","key":"10.1016\/j.pharep.2016.03.016_bib1390","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1194\/jlr.M051664","article-title":"Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans","volume":"55","author":"Bonde","year":"2014","journal-title":"J Lipid Res"},{"issue":"10","key":"10.1016\/j.pharep.2016.03.016_bib1395","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0905633","article-title":"Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia","volume":"362","author":"Ladenson","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharep.2016.03.016_bib1400","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.atherosclerosis.2014.09.035","article-title":"The thyroid receptor \u03b2 modulator GC-1 reduces atherosclerosis in ApoE deficient mice","volume":"237","author":"Kannisto","year":"2014","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.pharep.2016.03.016_bib1405","doi-asserted-by":"crossref","first-page":"e8722","DOI":"10.1371\/journal.pone.0008722","article-title":"The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice","volume":"5","author":"Tancevski","year":"2010","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.pharep.2016.03.016_bib1410","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/01.ATV.0000160551.21962.a7","article-title":"Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target","volume":"25","author":"Zalewski","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.pharep.2016.03.016_bib1415","doi-asserted-by":"crossref","first-page":"e89034","DOI":"10.1371\/journal.pone.0089034","article-title":"Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity: a randomized, controlled trial","volume":"9","author":"Johnson","year":"2014","journal-title":"PLOS ONE"},{"issue":"18","key":"10.1016\/j.pharep.2016.03.016_bib1420","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","article-title":"Darapladib for preventing ischemic events in stable coronary heart disease","volume":"370","author":"STABILITY Investigators","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.pharep.2016.03.016_bib1425","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jama.2014.11061","article-title":"Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial","volume":"312","author":"O\u2019Donoghue","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib1430","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jama.2013.282836","article-title":"Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial","volume":"311","author":"Nicholls","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pharep.2016.03.016_bib1435","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jacc.2013.07.050","article-title":"Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging","volume":"63","author":"Tawakol","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharep.2016.03.016_bib1440","unstructured":"Rilapladib in AD. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01428453?term=rilapladib&rank=3 [Accessed October 2015]."},{"issue":"9","key":"10.1016\/j.pharep.2016.03.016_bib1445","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jacc.2010.11.015","article-title":"Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial","volume":"57","author":"Nicholls","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pharep.2016.03.016_bib1450","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40256-015-0146-z","article-title":"Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, assure trial","volume":"16","author":"Nicholls","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.pharep.2016.03.016_bib1455","unstructured":"BETonMACE. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02586155?term=betonmace&rank=1 [Accessed 29.11.15]."},{"key":"10.1016\/j.pharep.2016.03.016_bib1460","first-page":"73","article-title":"Apolipoprotein AI-Milano: altered lipid binding properties in a human apolipoprotein variant","volume":"255","author":"Franceschini","year":"1988","journal-title":"Prog Clin Biol Res"},{"issue":"24","key":"10.1016\/j.pharep.2016.03.016_bib1465","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.jacc.2009.12.067","article-title":"A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome","volume":"55","author":"Waksman","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharep.2016.03.016_bib1470","unstructured":"CER-001; CARAT Study. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02484378?term=cer-001&rank=1 [Accessed September 2015]."},{"key":"10.1016\/j.pharep.2016.03.016_bib1475","unstructured":"CSL-112. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02108262?term=csl-112&rank=1 [Accessed September 2015]."},{"issue":"46","key":"10.1016\/j.pharep.2016.03.016_bib1480","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","article-title":"Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial","volume":"35","author":"Tardif","year":"2014","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.pharep.2016.03.016_bib1485","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002171","article-title":"Infusion of reconstituted high-density lipoprotein, CSL112, in patients with atherosclerosis: safety and pharmacokinetic results from a phase 2a randomized clinical trial","volume":"4","author":"Tricoci","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pharep.2016.03.016_bib1490","unstructured":"Statin pathway. Available from: https:\/\/en.wikipedia.org\/wiki\/File:StatinPathway_WP430.png [Accessed 10.12.15]."},{"key":"10.1016\/j.pharep.2016.03.016_bib1495","first-page":"23","article-title":"Perspektywy leczenia hipolipemizuj\u0105cego","volume":"4","author":"Okopie\u0144","year":"2015","journal-title":"ChorCywilPraktLek-KardiolDiabetol"},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib1500","first-page":"367","article-title":"Monocyte suppressing action of fenofibrate","volume":"57","author":"Okopie\u0144","year":"2005","journal-title":"Pharmacol Rep PR"},{"issue":"6","key":"10.1016\/j.pharep.2016.03.016_bib1505","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1734-1140(09)70176-8","article-title":"Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects","volume":"61","author":"Krysiak","year":"2009","journal-title":"Pharmacol Rep PR"},{"issue":"23","key":"10.1016\/j.pharep.2016.03.016_bib1510","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.jacc.2009.02.041","article-title":"Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes","volume":"53","author":"Fraley","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pharep.2016.03.016_bib1515","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.atherosclerosis.2010.05.027","article-title":"Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients","volume":"212","author":"Costet","year":"2010","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.pharep.2016.03.016_bib1520","doi-asserted-by":"crossref","first-page":"805","DOI":"10.5414\/CP201735","article-title":"Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose","volume":"50","author":"Buldak","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharep.2016.03.016_bib1525","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5551\/jat.1651","article-title":"Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia","volume":"17","author":"Nozue","year":"2010","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"10.1016\/j.pharep.2016.03.016_bib1530","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1210\/jc.2009-1952","article-title":"Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin","volume":"95","author":"Lakoski","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.pharep.2016.03.016_bib1535","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.atherosclerosis.2013.03.001","article-title":"Phytosterol capsules and serum cholesterol in hypercholesterolemia: a randomized controlled trial","volume":"228","author":"Ottestad","year":"2013","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.pharep.2016.03.016_bib1540","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1042\/CS20150193","article-title":"Serum proprotein convertase subtilisin\/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study","volume":"129","author":"Simonen","year":"2015","journal-title":"Clin Sci"},{"issue":"8","key":"10.1016\/j.pharep.2016.03.016_bib1545","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.nutres.2013.05.015","article-title":"Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects","volume":"33","author":"Cicero","year":"2013","journal-title":"Nutr Res"},{"issue":"12","key":"10.1016\/j.pharep.2016.03.016_bib1550","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/ATVBAHA.110.214130","article-title":"Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans","volume":"30","author":"Persson","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.pharep.2016.03.016_bib1555","doi-asserted-by":"crossref","first-page":"65A","DOI":"10.1016\/S0002-9149(05)80021-9","article-title":"Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group","volume":"76","author":"Bard","year":"1995","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.pharep.2016.03.016_bib1560","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archinte.1994.00420040119015","article-title":"Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia","volume":"154","author":"Farnier","year":"1994","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.pharep.2016.03.016_bib1565","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"23","key":"10.1016\/j.pharep.2016.03.016_bib1570","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"9860","key":"10.1016\/j.pharep.2016.03.016_bib1575","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pharep.2016.03.016_bib1580","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1172\/JCI80025","article-title":"Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects","volume":"125","author":"Millar","year":"2015","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib1585","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","article-title":"Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus","volume":"34","author":"Gutierrez","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"13","key":"10.1016\/j.pharep.2016.03.016_bib1590","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","article-title":"Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia","volume":"62","author":"Ballantyne","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"June (24)","key":"10.1016\/j.pharep.2016.03.016_bib1595","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/eurheartj\/eht088","article-title":"New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs","volume":"34","author":"Norata","year":"2013","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.pharep.2016.03.016_bib1600","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1161\/01.CIR.0000147777.12010.EF","article-title":"Effects of the acyl coenzyme A: cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions","volume":"110","author":"Tardif","year":"2004","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.pharep.2016.03.016_bib1605","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.jacc.2007.11.079","article-title":"The effect of darapladib on plasma lipoprotein-associated phospholipase a2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent","volume":"51","author":"Mohler","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.pharep.2016.03.016_bib1610","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12261","article-title":"Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome","volume":"277","author":"Angelin","year":"2015","journal-title":"J Intern Med"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016300093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016300093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:36:27Z","timestamp":1752611787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2016.03.016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":161,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S1734114016300093"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2016.03.016","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and future trends in the lipid lowering therapy","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2016.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}